AMLX
Amylyx Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -6.7% ·
share flow +16.1% ·
net new positions -7.1%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | +11 | 60.67M | $1.09B | +14 | −3 |
| Q1 2026 | 70 | -3 | 62.54M | $868.96M | +6 | −9 |
| Q4 2025 | 73 | 0 | 62.47M | $754.72M | n/a | n/a |
| Q3 2025 | 18 | +1 | 42.12M | $572.37M | +1 | n/a |
| Q2 2025 | 14 | -1 | 33.34M | $213.68M | n/a | −1 |
| Q1 2025 | 12 | +1 | 15.66M | $55.46M | +2 | −1 |
| Q4 2024 | 11 | 0 | 5.41M | $20.47M | +1 | −1 |
| Q3 2024 | 10 | +2 | 5.23M | $16.93M | +2 | n/a |
| Q2 2024 | 8 | n/a | 10.16M | $19.31M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 8.80M | +54.5% | $56.41M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 5.51M | n/a | $35.32M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 3 | Point72 Asset Management ✦ | 4.54M | +394.7% | $29.08M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 4 | The Vanguard Group ✦ (passive) | 4.50M | n/a | $28.83M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 5 | Fidelity (FMR) ✦ | 3.05M | n/a | $19.54M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Geode Capital Management ✦ (passive) | 1.69M | +109.9% | $10.85M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | Millennium Management ✦ | 1.51M | -50.9% | $9.69M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 1.24M | -54.9% | $7.97M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 9 | State Street Global Advisors ✦ (passive) | 1.01M | +285.4% | $6.47M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 558.85K | -26.7% | $3.58M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 396.20K | -23.1% | $2.54M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | Wellington Management ✦ | 288.62K | -0.7% | $1.85M | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
| 13 | D. E. Shaw & Co. ✦ | 151.50K | -43.9% | $971,128 | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 14 | T. Rowe Price ✦ | 91.39K | +58.4% | $586,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $875,353 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 170 holders, 113.99M shares, $1.58B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 30.00K sh · $830,904
Officer, Director · 29.55K sh · $950,040
Officer, Director · 919 sh · $30,464
Officer · 9.53K sh · $309,140
Officer · 11 sh · $367
Officer · 9.77K sh · $315,195
Officer · 1.04K sh · $34,626
Officer · 7.95K sh · $256,004
Officer · 2.08K sh · $68,864
Officer, Director · 29.02K sh · $932,553
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology